BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Furmonertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Furmonertinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06890182-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06890182)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resecta
 ble Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 furmonertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06890182
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06652048-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06652048)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: H
 igh-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanc
 ed NSCLC After Disease Progression on Third-generation EGFR-TKI\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/furmonertinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06652048
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04853342-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT04853342)
DESCRIPTION:Furmonertinib\, phase 3.\nStudy: To Assess the Efficacy and Saf
 ety of Furmonertinib Versus Placebo\, in Patients With Epidermal Growth Fa
 ctor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinom
 a\, Following Complete Tumour Resection With or Without Adjuvant Chemother
 apy\nEstimated primary completion: December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04853342
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06192849-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06192849)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 o Assess the Efficacy and Safety of Furmonertinib in Patients With Epiderm
 al Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small 
 Cell Lung Carcinoma\, Following Complete Tumour Resection With or Without 
 Adjuvant Chemotherapy\nEstimated primary completion: 1 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06192849
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319950-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06319950)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: H
 igh-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients
  With Brain Metastases\nEstimated primary completion: 30 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06319950
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06674343-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT06674343)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: F
 urmonertinib 160mg as First-line Treatment in Locally Advanced or Metastat
 ic NSCLC With EGFR Classical Mutations\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/furmone
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06674343
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971406-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06971406)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: H
 igh-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexe
 d in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptome
 ningeal Metastasis\nEstimated primary completion: 1 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06971406
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087223-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Furmonertinib: Phase 1/2 readout est. (NCT07087223)
DESCRIPTION:Furmonertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients Wit
 h c-Met Amplification After EGFR-TKI Failure\nEstimated primary completion
 : April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/furmone
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07087223
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07092202-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Furmonertinib: Phase 4 readout est. (NCT07092202)
DESCRIPTION:Furmonertinib\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Combined With Intrathecal Injection for the Treatment of EGFR
  Mutant NSCLC With Leptomeningeal Metastases\nEstimated primary completion
 : 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/furmone
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07092202
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06945705-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270902
DTEND;VALUE=DATE:20270903
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06945705)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Tre
 atment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastas
 is\nEstimated primary completion: 2 September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06945705
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07482605-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07482605)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 urmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion\nEsti
 mated primary completion: 30 October 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07482605
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06956001-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT06956001)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Versus Platinum Based Chemotherapy as First-line Treatment fo
 r NSCLC With EGFR PACC or EGFR l861q Mutation\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fur
 monertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06956001
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655622-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20271203
DTEND;VALUE=DATE:20271204
SUMMARY:Furmonertinib: Phase 1/2 readout est. (NCT07655622)
DESCRIPTION:Furmonertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non
 -small Cell Lung Cancer and High PD-L1 Expression\nEstimated primary compl
 etion: 3 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/furmonertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07655622
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668103-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06668103)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonerti
 nib\nEstimated primary completion: 30 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06668103
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548060-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280122
DTEND;VALUE=DATE:20280123
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07548060)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertin
 ib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progr
 essed After EGFR-TKI and Platinum-Based Chemotherapy\nEstimated primary co
 mpletion: 22 January 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/furmonertinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07548060
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07517640-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07517640)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: C
 ombining Furmonertinib With Local Therapy for Inoperable Early-stage Lung 
 Cancer: A Phase II Trial\nEstimated primary completion: 1 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07517640
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807722-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07807722)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum
 -Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC\nEstimated p
 rimary completion: March 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/furmonertinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07807722
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868732-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Furmonertinib: Phase 1 readout est. (NCT06868732)
DESCRIPTION:Furmonertinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: E
 valuation of JSKN016 Combination Therapy in Subjects With NSCLC\nEstimated
  primary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/furmonertinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06868732
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987826-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT05987826)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB
  EGFR Sensitive Mutant NSCLC\nEstimated primary completion: August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05987826
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348965-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Furmonertinib: Phase na readout est. (NCT07348965)
DESCRIPTION:Furmonertinib\, phase na\, Non-Small Cell Lung Cancer.\nStudy: 
 Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal
  Metastasis\nEstimated primary completion: 30 September 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07348965
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010419-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT07010419)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo f
 or Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Unco
 mmon Epidermal Growth Factor Receptor (EGFR) Mutations\, Following Complet
 e Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）\nE
 stimated primary completion: 31 October 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07010419
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969781-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Furmonertinib: Phase na readout est. (NCT06969781)
DESCRIPTION:Furmonertinib\, phase na\, Non-Small Cell Lung Cancer.\nStudy: 
 MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Canc
 er\nEstimated primary completion: December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06969781
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304739-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07304739)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 urmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radio
 therapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and L
 eptomeningeal Metastases\nEstimated primary completion: 30 December 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07304739
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622186-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07622186)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SKB571 Combination Therapy in Participants With Non-Small Cell L
 ung Cancer (NSCLC)\nEstimated primary completion: 31 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07622186
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185997-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT07185997)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Invest
 igator's Choice of EGFR Inhibitor as First-Line Treatment in Participants 
 Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C
 -Helix Compressing (PACC) Uncommon Mutations\nEstimated primary completion
 : February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/furm
 onertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07185997
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970639-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT06970639)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy V
 ersus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR)
  Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NS
 CLC) and Brain Metastases\nEstimated primary completion: March 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06970639
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07661173-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07661173)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided 
 by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-muta
 ted Non-small Cell Lung Cancer\nEstimated primary completion: 6 March 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07661173
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229599-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Furmonertinib: Phase 1/2 readout est. (NCT07229599)
DESCRIPTION:Furmonertinib\, phase 1/2.\nStudy: A Study of MHB036C Combined 
 With Anti-tumor Therapies in Patients With Advanced Lung Cancer\nEstimated
  primary completion: May 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/furmonertinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07229599
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182708-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07182708)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: H
 igh-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resecta
 ble EGFRm Stage II-IIIB NSCLC\nEstimated primary completion: 30 December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071827
 08
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622706-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07622706)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-m
 utated Lung Adenocarcinoma\nEstimated primary completion: 30 December 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07622706
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298148-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07298148)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrat
 ing SD After 8 Week Induction With Firmonertinib 80 mg\nEstimated primary 
 completion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/furmonertinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07298148
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314216-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07314216)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Combined With Definitive Radiotherapy in Stage III Unresectab
 le EGFR Uncommon Mutant Pulmonary Adenocarcinoma\nEstimated primary comple
 tion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/furmonertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07314216
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07878871-1983@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07878871)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III
  Lung Cancer: A Phase II Study\nEstimated primary completion: December 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07878871
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
